Amylyx Pharmaceuticals (AMLX) Operating Margin: 2021-2024
Historic Operating Margin for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -155.00%.
- Amylyx Pharmaceuticals' Operating Margin fell 15652.00% to -155.00% in Q4 2024 from the same period last year, while for Dec 2024 it was -270.59%, marking a year-over-year decrease of 27959.00%. This contributed to the annual value of -275.44% for FY2024, which is 28443.00% down from last year.
- Amylyx Pharmaceuticals' Operating Margin amounted to -155.00% in Q4 2024, which was up 99.15% from -18,187.74% recorded in Q3 2024.
- In the past 5 years, Amylyx Pharmaceuticals' Operating Margin registered a high of 18.63% during Q2 2023, and its lowest value of -18,187.74% during Q3 2024.
- Over the past 3 years, Amylyx Pharmaceuticals' median Operating Margin value was -146.39% (recorded in 2024), while the average stood at -3,606.76%.
- In the last 5 years, Amylyx Pharmaceuticals' Operating Margin soared by 1,001,326bps in 2023 and then slumped by 1,820,447bps in 2024.
- Quarterly analysis of 4 years shows Amylyx Pharmaceuticals' Operating Margin stood at -8,041.40% in 2021, then crashed by 195,512bps to -167.91% in 2022, then soared by 16,944bps to 1.53% in 2023, then tumbled by 15,652bps to -155.00% in 2024.
- Its Operating Margin stands at -155.00% for Q4 2024, versus -18,187.74% for Q3 2024 and -7,457.09% for Q2 2024.